1. Nonhematopoietic functions of erythropoietin, particularly the effect of Epo on the growth and survival of tumor cells.
2. The functional significance of the erythropoietin receptor (EpoR) in prostate and ovarian cancer.
3. The role of the EpoR in the pathogenesis and progression of breast cancer.
4. Hematopoietic growth factors and their receptors - including a) the role of receptor crosstalk in modulation of growth factor function, b) interaction of thrombopoietin (TPO) with the erythropoietin (EPO) receptor on erythroid progenitors, and c) non-hematopoietic functions of hematopoietic growth factors
Jeong J-Y, Feldman L, Solar P, Szenajch J, Sytkowski AJ. Characterization of the erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells. Int J Cancer, 2008; 122(2):274-280.
Solar P, Feldman L, Jeong J-Y, Busingye JR, Sytkowski AJ. Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel-resistant phenotype. Int J Cancer, 2008; 122(2):281-288.
Feldman L, Wang Y, Rhim JS, Bhattacharya N, Loda M, Sytkowski AJ. Erythropoietin Stimulates Growth and STAT5 Phosphorylation in Human Prostate Epithelial and Prostate Cancer Cells. The Prostate, 2006; 66:135-145.
L Feldman, K Cui, C Rouleau. A functional erythropoietin receptor is necessary for the action of thrombopoietin on erythroid cells lacking c-mpl. Exp Hematol 2004; 32:140-148.
L Feldman, A J Sytkowski. Pleiotrophic Actions of Erythropoietin. Environmental Health and Preventive Medicine, 2003; 7:239-245.
External Recognition:
2003 - International Conference on Radiation Research (Brisbane, Australia), invited speaker: Functional Erythropoietin Receptors on Tumor Cells
2004 - consultant, FDA Oncologic Drugs Advisory Committee
2008 - session co-chair and speaker, Era of Hope Breast Cancer meeting (Baltimore, MD - June 25-28)
2008 - speaker, NIH Workshop on Erythropoietin Receptor Expression in Non-hematopoietic Cells (Bethesda, MD - Sept 8-9)
